Medical AI needs a visible evidence history
INCOPREA / RESEARCH
AI & medicine · Technology and policy commentary · Sources reviewed October 30, 2026
The evidence attached to medical AI has a date. Keeping that evidence useful is a continuing job.
Imagine a hospital evaluating an image-analysis tool and using it for several years. Its code might remain fixed while the surroundings change: different equipment, patient populations, recording practices or clinical routines. This is an illustrative scenario, not a report of a particular failure. It explains why asking whether a model once worked is different from asking whether it still works here.
Watch the model and its surroundings
FDA's January 2025 lifecycle draft discusses performance monitoring, changing inputs and the context of use. It proposes planning for changes in performance after deployment, including possible responses and communication to users. This treats maintenance as part of the product. Importantly, the official guidance page still identifies this document as draft, not for implementation at our review cutoff. Its proposals should not be reported as a final rule. Check the draft's status and text.
Plan a change before making it
A separate FDA document is final: the August 2025 guidance on predetermined change control plans for AI-enabled device software. It describes a plan covering specified modifications, methods for developing, validating and implementing them, and an assessment of their impact. FDA reviews that plan within a device's marketing submission. The approach can allow modifications described in the reviewed plan without a new marketing submission for each one; it is not an unrestricted permission to change any feature. Read the final PCCP guidance.
These documents concern medical devices and should not be generalized to every chatbot or administrative tool. Neither the existence of a change plan nor a version number demonstrates that a product learns continuously from every patient. The relevant questions are what changed, what was checked and which uses the evidence supports.
An evidence history people can use
Our editorial proposal is a readable evidence history alongside the software history: version and date, intended use, evaluation population, known limits, observed performance and the reason for each material change. An update that improves one task should not silently acquire credit for another task that was never tested.
The joint FDA, Health Canada and MHRA transparency principles recommend timely communication of updates and information about performance monitoring. Their emphasis is useful: maintenance includes helping users understand the change, not simply installing it. Read the transparency principles.
A clear history would let a clinician connect a published result to the version on the screen. It would also let a researcher distinguish a promising update from a demonstrated improvement. Those are modest documentation goals, but they make larger claims easier to examine.
Comments
Post a Comment